Seeking Alpha
18 Aug 2026, 14:52 UTC · 13w ago
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Impact · against what's priced in
Edgewise Therapeutics' valuation is significantly enhanced by the combination of robust Phase 2 efficacy for EDG-7500 and a massive capital infusion from Servier. The $1.55B sale effectively eliminates dilution risk for the next several years while maintaining substantial milestone upside.
- EWTX+0.80
No priced-in read yet





